Table 1.

FDA-approved PD-L1/PD-1 inhibitors for cancer treatment.

Drug name	Target	Cancer types
Pembrolizumab	PD-1	melanoma, non-small cell lung cancer, head and neck squamous cell cancer, urothelial carcinoma, renal cell carcinoma, classical Hodgkin lymphoma, microsatellite instability-high solid cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, primary mediastinal large B-cell lymphoma
Nivolumab	PD-1	metastatic small cell lung cancer, metastatic non-small cell lung cancer, metastatic melanoma, metastatic urothelial carcinoma, metastatic colorectal cancer, hepatocellular carcinoma, advanced renal cell carcinoma, classical Hodgkin lymphoma, metastatic head, and neck squamous cell cancer,
Atezolizumab	PD-L1	urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer
Durvalumab	PD-L1	locally advanced non-small cell lung cancer, small cell lung cancer, metastatic urothelial carcinoma
Avelumab	PD-L1	locally advanced or metastatic urothelial carcinoma, metastatic Merkel cell carcinoma